Back to Journals » Clinical Ophthalmology » Volume 9

Toxic anterior segment syndrome and intracameral injection of cefuroxime axetil

Authors Gardner S, Barry P, Cordovés L

Received 7 July 2015

Accepted for publication 16 July 2015

Published 3 October 2015 Volume 2015:9 Pages 1865—1867

DOI https://doi.org/10.2147/OPTH.S91943

Checked for plagiarism Yes

Editor who approved publication: Dr Scott Fraser


Susanne Gardner,1 Peter Barry,2 Luis Cordovés3

1European Society of Cataract and Refractive Surgery, Dublin, Ireland; 2Ophthalmic Surgery, St Vincents University Hospitals Group, Dublin, Ireland; 3Retina and Vitreous Section, Ophthalmology Service, Hospital Universitario de Canarias, Spain

We read with concern the findings of toxic anterior segment syndrome in patients receiving intracameral injection of cefuroxime axetil, as described in the report by Çakir et al1 in the March 2015 issue of Clinical Ophthalmology. Notably, the authors state that the form of cefuroxime used to extemporaneously compound cefuroxime for intracameral injection was cefuroxime axetil and that 17 cases of toxic anterior segment syndrome ensued. With over one million doses of intracameral cefuroxime administered to date, and with extensive clinical experience,2 the unfortunate scenario described by the authors has not been realized elsewhere.

View original article by Çakır et al

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]